نتائج البحث

The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis.

• Authors : Hu X; Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.; Tang X

Subjects: Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/therapeutic use ; Infliximab*/Infliximab*/Infliximab*/therapeutic use ; Remission Induction*

• Source: BMC gastroenterology [BMC Gastroenterol] 2024 Nov 12; Vol. 24 (1), pp. 406. Date of Electronic Publication: 2024 Nov 12.Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X

تفاصيل العنوان

Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure.

• Authors : Bae JH; Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.; Park JB

Subjects: Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Infliximab*/Infliximab*/Infliximab*/administration & dosage ; Infliximab*/Infliximab*/Infliximab*/pharmacokinetics

• Source: Gut and liver [Gut Liver] 2024 Jul 15; Vol. 18 (4), pp. 667-676. Date of Electronic Publication: 2024 Jun 05.Publisher: Editorial Office of Gut and Liver Country of Publication: Korea (South) NLM ID: 101316452 Publication Model: Print-Electronic Cited Medium:

تفاصيل العنوان

Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.

• Authors : Krugliak Cleveland N; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA. .; Ghosh S

Subjects: Adalimumab*/Adalimumab*/Adalimumab*/therapeutic use ; Adalimumab*/Adalimumab*/Adalimumab*/adverse effects ; Infliximab*/Infliximab*/Infliximab*/therapeutic use

• Source: BMC gastroenterology [BMC Gastroenterol] 2024 Sep 17; Vol. 24 (1), pp. 314. Date of Electronic Publication: 2024 Sep 17.Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X

تفاصيل العنوان

Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.

• Authors : Alharbi O; Gastroenterology Section, King Khalid University Hospital, College of Medicine, King Saud University, Riyadh, Saudi Arabia.; Hamed W

Subjects: Biological Products* ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/epidemiology

• Source: Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2023 May-Jun; Vol. 29 (3), pp. 164-170.Publisher: Medknow Publications Country of Publication: India NLM ID: 9516979 Publication Model: Print Cited Medium: Internet ISSN: 1998-4049

تفاصيل العنوان

Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis.

• Authors : Gilmore R; Department of Gastroenterology, Mater Hospital, Brisbane, Australia.; Department of Medicine, University of Queensland, Brisbane, Australia.

Subjects: Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/surgery ; Heterocyclic Compounds, 3-Ring*; Humans

• Source: Journal of Crohn's & colitis [J Crohns Colitis] 2023 Dec 30; Vol. 17 (12), pp. 2033-2036.Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

90K/Mac-2 BP Is a New Predictive Biomarker of Response to Infliximab Therapy in IBD Patients.

• Authors : Pesole PL; National Institute of Gastroenterology-IRCCS, 'Saverio de Bellis', 70013 Castellana Grotte, Italy.; Liso M

Subjects: Biological Products*/Biological Products*/Biological Products*/therapeutic use ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy ; Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy

• Source: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 16; Vol. 24 (4). Date of Electronic Publication: 2023 Feb 16.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Long-term effectiveness and safety of infliximab-biosimilar: A multicenter Phoenix retrospective cohort study.

• Authors : Kazama T; Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.; Ando K

Subjects: Crohn Disease*/Crohn Disease*/Crohn Disease*/drug therapy ; Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/Biosimilar Pharmaceuticals*/adverse effects ; Colitis, Ulcerative*/Colitis, Ulcerative*/Colitis, Ulcerative*/drug therapy

• Source: PloS one [PLoS One] 2023 Sep 12; Vol. 18 (9), pp. e0288393. Date of Electronic Publication: 2023 Sep 12 (Print Publication: 2023).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis

• Source: Comparison of Short and Long-term Efficacy Between Infliximab and Adalimumab on Patients With Ulcerative Colitis - a Retrospective Observational Multicenter Cohort

تفاصيل العنوان

EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis (EFFICACI)

• Source: EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized

تفاصيل العنوان

Efficiency of Orexin-A for Inflammatory Flare and Mucosal Healing in Experimental Colitis: Comparison with the Anti-TNF Alpha Infliximab.

• Authors : Blais A; UMR-PNCA, Université Paris-Saclay, AgroParisTech, INRAE, 91120 Palaiseau, France.; Lan A

Subjects: Colitis*/Colitis*/Colitis*/chemically induced ; Colitis*/Colitis*/Colitis*/drug therapy ; Colitis*/Colitis*/Colitis*/metabolism

• Source: International journal of molecular sciences [Int J Mol Sci] 2023 May 31; Vol. 24 (11). Date of Electronic Publication: 2023 May 31.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان